GPC Biotech to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference

Martinsried/Munich (Germany) and Waltham, Mass. and Princeton, N.J., May 8, 2006 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Company will be presenting at the Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco.

The presentation will be given by Mirko Scherer, Ph.D., Chief Financial Officer of the Company and is scheduled for Monday, May 15, 2006 at 12:20 CET/6:20 AM EDT. The presentation will be webcast live and will be accessible through the GPC Biotech Web site at www.gpc-biotech.com. A replay will be available via the Web site following the live event.





GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate – satraplatin – has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at www.gpc-biotech.com.

Contact Information

Laurie Doyle

Associate Director, Investor Relations & Corporate Communications

GPC Biotech AG

Contact via E-mail